3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis
NCT ID: NCT01794741
Last Updated: 2015-03-31
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
405 participants
INTERVENTIONAL
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)
NCT01915823
Dymista Allergen Chamber - Onset of Action Study
NCT04652245
A Study Comparing the Bioequivalence of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (Apotex, Inc.) to That of Dymista™ Nasal Spray (Meda Pharmaceuticals, Inc.) in the Treatment of Seasonal Allergic Rhinitis
NCT02279563
Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis
NCT02402465
DYmista NAsal Spray in CHInese Patients
NCT03599791
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dymista nasal spray
azelastine 137mcg per spray/fluticasone propionate 50mcg per spray one spray per nostril twice a day for three months
Dymista Nasal Spray
fluticasone propionate nasal spray
fluticasone propionate nasal spray 50mcg per spray per nostril twice a day
Fluticasone propionate nasal spray
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dymista Nasal Spray
Fluticasone propionate nasal spray
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A history of allergic rhinitis (AR)
* The parent/caregiver must provide written informed consent and the child must provide assent
* Willing and able to comply with the study requirements
* Require treatment with Dymista Nasal Spray, based on the Investigator's assessment (based on medical history, physical examination, etc.) of the subjects' clinical condition, at both the Screening and Randomization Visits
* General good health and free of any disease or concomitant treatment that could interfere with the interpretation of the study results as determined by the investigator or the sponsor's medical officer
* Subjects receiving immunotherapy injections (antigen desensitization) must be on a stable maintenance regimen for at least 30 days before the first study visit (adjustments to regimen following a brief period of missed injections do not preclude participation)
Exclusion Criteria
* Nasal disease(s) likely to affect deposition of intranasal medication, such as acute or chronic sinusitis, rhinitis medicamentosa, clinically significant polyposis or clinically significant nasal structural abnormalities
* Nasal surgery or sinus surgery within the previous year
* The use of any investigational drug within 30 days prior to Visit 1. No investigational products are permitted for use during the conduct of this study
* Presence of any hypersensitivity to azelastine hydrochloride and/or fluticasone propionate or drugs similar to azelastine hydrochloride and/or fluticasone propionate
* Respiratory tract infections within two weeks prior to Visit 1.
* Subjects with significant pulmonary disease including asthma. Subjects with intermittent asthma who only require short-acting inhaled bronchodilators (not more often than twice per week) and who do not have nocturnal awakening as a result of asthma are eligible for enrollment
* Chronic obstructive sleep apnea syndrome (clinical diagnosis)
* Existence of any surgical or medical condition, which in the opinion of the investigator or sponsor's medical monitor, might significantly alter the absorption, distribution, metabolism, or excretion of study drug or that might significantly affect the subject's ability to complete this trial
* Clinically relevant abnormal physical findings or laboratory results which, in the opinion of the investigator, would interfere with the objectives of the study or that may preclude compliance with the study procedures
* Family members of research center or private practice personnel who are directly involved in this study are excluded
* Members of the same family cannot enroll in the study at the same time.
* Subjects who have used medications or therapies that could interfere with safety evaluations (see Sections 4.0 and 5.0) and have not had the proper washouts from these medications or therapies
* Any behavioral condition which could affect subject's ability to accurately report symptoms to the caregiver such as developmental delay, attention deficit disorder, and autism
* Positive pregnancy test in female subjects ≥ 9 years of age
* Females who are pregnant or nursing practicing a medically acceptable method of contraception
* Subjects who fail to complete the symptom diary during the lead-in period, defined as missing data for \>50% of entries
4 Years
11 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Meda Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nancy Ruiz, M.D.
Role: STUDY_DIRECTOR
Sponsor GmbH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Center of Alabama,LLC
Birmingham, Alabama, United States
Little Rock Allergy and Asthma Clinical research Center
Little Rock, Alaska, United States
West Coast Clinical Trials
Costa Mesa, California, United States
Allergy & Asthma Care Center of So. Cal
Long Beach, California, United States
Southern California Research
Mission Viejo, California, United States
Allergy Associates Medical Group Inc
San Diego, California, United States
Allergy & Asthma Associates of Santa Clara Valley Research Cntr
San Jose, California, United States
Storms Clinical Research Institute
Colorado Springs, Colorado, United States
Colorado Allergy and Asthma Centers, PC
Denver, Colorado, United States
Asthma and Allergy Associates, PC
Pueblo, Colorado, United States
Allergy and Asthma Care of Florida
Ocala, Florida, United States
Atlanta Allergy and Asthma Clinic
Stockbridge, Georgia, United States
Idaho Allergy
Eagle, Idaho, United States
Sneeze, Wheeze and Itch Associates
Normal, Illinois, United States
Clinical Research Institute of Indiana
Indianapolis, Indiana, United States
Family Allergy and Asthma Reserach
Louisville, Kentucky, United States
Respiratory Medicine Research Institute of Michigan
Ypsilanti, Michigan, United States
Clinical Reseacrh Institute
Minneapolis, Minnesota, United States
The Clinical Research Center
St Louis, Missouri, United States
Clinical Research of the Ozarks,Inc
Warrensburg, Missouri, United States
Midwest Allergy and Asthma Clinic
Omaha, Nebraska, United States
The Asthma and Allergy Center, PC
Papillion, Nebraska, United States
Atlantic Research Center
Ocean City, New Jersey, United States
Asthma, Sinus & Allergy Centers, LLC
Warren Township, New Jersey, United States
North Carolina Clinical Research
Raleigh, North Carolina, United States
Bernstein Clinical Research Center
Cincinnati, Ohio, United States
Allergy, Asthma & Clinical Research Center
Oklahoma City, Oklahoma, United States
Oklahoma Institute of Allergy and Asthma
Oklahoma City, Oklahoma, United States
Baker Allergy Asthma & Dermatology Ctr LLC
Lake Oswego, Oregon, United States
Allergy and Asthma Specialist PC
Blue Bell, Pennsylvania, United States
National Allergy, Asthna & Urticaria Centers of Charleston Pa
Charleston, Pennsylvania, United States
Allergy and Clinical Immunology Associates
Pittsburgh, Pennsylvania, United States
Asthma and Allergy Research Associate
Upland, Pennsylvania, United States
ADAC Research, PA
Greenville, South Carolina, United States
AARA Research Center
Dallas, Texas, United States
Texas Allergy Research Center
Dallas, Texas, United States
Central Texas Health Research
New Braunfels, Texas, United States
Paul H Ratner,MD
San Antonio, Texas, United States
Live Oak Allergy and Asthma Clinic
San Antonio, Texas, United States
Allergy Asthma Research Institute
Waco, Texas, United States
Pediatric Allergy,Asthma and Immunology/Allergy& Asthma care of Waco
Waco, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Berger W, Sher E, Gawchik S, Fineman S. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. Allergy Asthma Proc. 2018 Mar 1;39(2):110-116. doi: 10.2500/aap.2018.39.4116.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MP 4007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.